United Therapeutics | UTHR - Cash And Equivalent



United Therapeutics reported $1.59B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Amarin USD 119.52M 1.51M Mar/2025
Ardelyx USD 90.04M 41.39M Jun/2025
Baxter International USD 2.29B 530M Mar/2025
Bayer EUR 4.56B 542M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Halozyme Therapeutics USD 61.86M 114.47M Jun/2025
Insmed USD 1.28B 881.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Moderna USD 1.28B 344M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
Teva Pharmaceutical Industries USD 2.16B 464M Jun/2025
United Therapeutics USD 1.59B 306.8M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025